These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31964532)

  • 21. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
    Batchu SN; Yerra VG; Liu Y; Advani SL; Klein T; Advani A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model.
    Wang SC; Wang XY; Liu CT; Chou RH; Chen ZB; Huang PH; Lin SJ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis.
    Kurosawa T; Li Y; Sudo M; Haruta H; Hagikura K; Takayama T; Hiro T; Shiomi M; Hao H; Matsumoto T; Hirayama A; Okumura Y
    Heart Vessels; 2021 Jan; 36(1):127-135. PubMed ID: 32914346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
    Arulmozhiraja S; Matsuo N; Ishitsubo E; Okazaki S; Shimano H; Tokiwa H
    PLoS One; 2016; 11(11):e0166275. PubMed ID: 27832184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
    Ikedo T; Minami M; Kataoka H; Hayashi K; Nagata M; Fujikawa R; Higuchi S; Yasui M; Aoki T; Fukuda M; Yokode M; Miyamoto S
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28630262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
    Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
    Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
    Luippold G; Mark M; Klein T; Amann K; Daniel C
    Diabetes Res Clin Pract; 2018 Sep; 143():199-203. PubMed ID: 30031047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway.
    Suda M; Shimizu I; Yoshida Y; Hayashi Y; Ikegami R; Katsuumi G; Wakasugi T; Yoshida Y; Okuda S; Soga T; Minamino T
    PLoS One; 2017; 12(8):e0182422. PubMed ID: 28771625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.
    Kern M; Klöting N; Niessen HG; Thomas L; Stiller D; Mark M; Klein T; Blüher M
    PLoS One; 2012; 7(6):e38744. PubMed ID: 22761701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Abouelkheir M; El-Metwally TH
    Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
    Wang X; Ding Z; Yang F; Dai Y; Chen P; Theus S; Singh S; Budhiraja M; Mehta JL
    Clin Sci (Lond); 2016 Aug; 130(15):1353-62. PubMed ID: 27129181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
    Shah Z; Kampfrath T; Deiuliis JA; Zhong J; Pineda C; Ying Z; Xu X; Lu B; Moffatt-Bruce S; Durairaj R; Sun Q; Mihai G; Maiseyeu A; Rajagopalan S
    Circulation; 2011 Nov; 124(21):2338-49. PubMed ID: 22007077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.
    Manrique C; Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Martinez-Lemus LA; Ramirez-Perez FI; Klein T; Meininger GA; DeMarco VG
    Cardiovasc Diabetol; 2016 Jul; 15():94. PubMed ID: 27391040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
    Shinjo T; Nakatsu Y; Iwashita M; Sano T; Sakoda H; Ishihara H; Kushiyama A; Fujishiro M; Fukushima T; Tsuchiya Y; Kamata H; Nishimura F; Asano T
    Am J Physiol Endocrinol Metab; 2015 Aug; 309(3):E214-23. PubMed ID: 26015438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potential contribution of dipeptidyl peptidase-4 by the mediation of monocyte differentiation in the development and progression of abdominal aortic aneurysms.
    Lu HY; Huang CY; Shih CM; Lin YW; Tsai CS; Lin FY; Shih CC
    J Vasc Surg; 2017 Oct; 66(4):1217-1226.e1. PubMed ID: 27887857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats.
    Łupina M; Wąsik A; Baranowska-Bosiacka I; Tarnowski M; Słowik T; Listos P; Kotlińska J; Kosik-Bogacka D; Gutowska I; Listos J
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
    Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
    Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.